Bio-Techne reported a 4% year-over-year revenue increase in fiscal fourth quarter 2025, driven by growth in cell therapy and protein analysis instruments amid a resilient pharma market. The company posted adjusted EPS exceeding analyst estimates despite a net loss during the quarter. Additionally, Bio-Techne announced the sale of its Exosome Diagnostics business to MDxHealth for $15 million in cash and stock, a transaction expected to close soon, aimed at sharpening Bio-Techne’s focus on innovative, high-margin life science and diagnostic products.